Please login to the form below

Not currently logged in
Email:
Password:

Genentech’s Sunil Agarwal joins rare disease firm

He will serve as chief medical officer at Ultragenyx

Dr Sunil Agarwal has left his senior role at Genentech to join rare disease specialist Ultragenyx Pharmaceutical as its chief medical officer.

Dr Agarwal was most recently global head of clinical development for immunology and infectious diseases, metabolism, neuroscience and ophthalmology at Genentech, which has been the biotech arm of Roche since its acquisition in 2009.

He spent just over 10 years at Genentech where his positions included senior VP for immunology and infectious diseases and VP for rheumatology.

In his new role at Ultragenyx Dr Agarwal will lead the California-based company's clinical operations, regulatory affairs and pharmacovigilance efforts as it advances its pipeline of orphan products for rare and ultra-rare diseases. These include KRN23, a drug in development for people who have low levels of phosphate in the blood.

Commenting on his appointment Dr Agarwal said: “To develop novel therapies for these patients who have no approved treatments and to help push the science forward in these rare genetic diseases is something I am thrilled to be a part of.”

25th July 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics